Elutia Inc
NASDAQ:ELUT

Watchlist Manager
Elutia Inc Logo
Elutia Inc
NASDAQ:ELUT
Watchlist
Price: 1.04 USD -0.95% Market Closed
Market Cap: $44.4m

Net Margin

-125.6%
Current
Improving
by 3.2%
vs 3-y average of -128.7%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-125.6%
=
Net Income
$-26.5m
/
Revenue
$21.1m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-125.6%
=
Net Income
$-26.5m
/
Revenue
$21.1m

Peer Comparison

Country Company Market Cap Net
Margin
US
Elutia Inc
NASDAQ:ELUT
44.3m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
393.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
172.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
88.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.4B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 86% of companies in the United States of America
Percentile
14th
Based on 15 072 companies
14th percentile
-125.6%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Elutia Inc
Glance View

Market Cap
44.4m USD
Industry
Biotechnology

Aziyo Biologics, Inc. operates as a biotechnology company. The company is headquartered in Silver Spring, Maryland and currently employs 151 full-time employees. The company went IPO on 2020-10-08. The firm is a commercial-stage company that serves two markets with products based on its biomatrix platforms. The company offers a drug-eluting biologic technology: a fusion of natural biologic material and extended antibiotic release, for device implantation and soft tissue reconstruction. Its first product is CanGaroo Envelope, used for the stabilization of implantable cardiac devices, such as pacemakers and defibrillators. Its second product is SimpliDerm Acellular Dermal Matrix, used primarily in breast reconstruction following mastectomy. The company is also engaged in the development of CanGaroo RM, which adds the antibiotics rifampin and minocycline for sustained delivery directly to the surgical site. The Company’s products are used by electrophysiologists and plastic surgeons.

ELUT Intrinsic Value
1.45 USD
Undervaluation 28%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-125.6%
=
Net Income
$-26.5m
/
Revenue
$21.1m
What is Elutia Inc's current Net Margin?

The current Net Margin for Elutia Inc is -125.6%, which is above its 3-year median of -128.7%.

How has Net Margin changed over time?

Over the last 3 years, Elutia Inc’s Net Margin has decreased from -77.1% to -125.6%. During this period, it reached a low of -221.3% on Dec 31, 2024 and a high of -64.5% on Mar 31, 2023.

Back to Top